GlassScriptPhysician profile
Joshua Twito
NPI 1598384448
$2,675.81
in general payments reported to CMS, 2019-2025
18 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $294 · 2024: $917 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996 · Travel and Lodging: $528 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.75 |
| Travel and Lodging | $528.08 |
| Education | $151.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $528.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $416.81 | 2023-2025 | Fasenra, Tezspire, Breztri |
| Actelion Pharmaceuticals US, INC. | $328.10 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Olympus America INC. | $298.33 | 2024-2025 | Spiration Valve System, Single-Use Flexible Video Bronchoscope |
| Merck Sharp & Dohme LLC | $173.87 | 2023-2025 | Zerbaxa, Winrevair, Dificid |
| Inari Medical, INC. | $170.08 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insmed, INC. | $127.33 | 2023-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $120.01 | 2024-2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.26 | 2023-2024 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $99.80 | 2023-2025 | Glassia |
| Pinnacle Biologics, INC | $61.41 | 2025 | Photofrin |
| Inspire Medical Systems, INC. | $57.97 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $43.12 | 2024-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $37.61 | 2024-2025 | Dupixent |
| La Jolla Pharmaceutical Company | $36.86 | 2024-2025 | Giapreza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.70 | 2024 | Xarelto |
| Daiichi Sankyo INC. | $22.84 | 2024 | Enhertu |
| Genzyme Corporation | $17.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Twito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.